Takeda entered into a licensing agreement with Selecta Biosciences to develop targeted, next-generation gene therapies for two indications within the field of lysosomal storage disorders, the latter company said Monday. The collaboration will utilise Selecta's ImmTOR platform, which is designed to enhance transgene expression and address adeno-associated virus (AAV) vector immunogenicity constraints.
Madhu Natarajan, head of Takeda's rare diseases drug discovery unit, noted that the "ImmTOR platform is designed to mitigate unwanted immune responses allowing for redosing, which could have broad applicability across our gene therapy programs for a range of diseases."
Under the agreed terms, Takeda will make an undisclosed upfront payment to Selecta, with the latter eligible to receive up to $1.1 billion in milestones as well as tiered sales royalties.
To read more Top Story articles, click here.